Cargando…
Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
BACKGROUND: Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [(18)F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and id...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087750/ https://www.ncbi.nlm.nih.gov/pubmed/33929626 http://dx.doi.org/10.1186/s13550-021-00783-w |
_version_ | 1783686718750195712 |
---|---|
author | Ahmadi Bidakhvidi, Niloefar Laenen, Annouschka Jentjens, Sander Deroose, Christophe M. Van Laere, Koen De Wever, Liesbeth Mai, Cindy Berghen, Charlien De Meerleer, Gert Haustermans, Karin Joniau, Steven Everaerts, Wouter Goffin, Karolien |
author_facet | Ahmadi Bidakhvidi, Niloefar Laenen, Annouschka Jentjens, Sander Deroose, Christophe M. Van Laere, Koen De Wever, Liesbeth Mai, Cindy Berghen, Charlien De Meerleer, Gert Haustermans, Karin Joniau, Steven Everaerts, Wouter Goffin, Karolien |
author_sort | Ahmadi Bidakhvidi, Niloefar |
collection | PubMed |
description | BACKGROUND: Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [(18)F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and identify parameters that predict scan positivity as well as the type and number of detected lesions. This monocentric retrospective study included 137 PCa patients with biochemical recurrence who underwent one or more [(18)F]PSMA-1007-PET/CT scans between August 2018 and June 2019. PET-positive malignant lesions were classified as local recurrence, lymph node (LN), bone or soft tissue lesions. The association between biochemical/paraclinical parameters, as PSA value, PSA doubling time, PSA velocity, Gleason score (GS) and androgen deprivation therapy (ADT), and scan positivity as well as type and number of detected lesions was evaluated using logistic regression analysis (binary outcomes) and Poisson models (count-type outcomes). RESULTS: We included 175 [(18)F]PSMA-1007-PET/CT scans after radical prostatectomy (78%), external beam radiation therapy (8.8%), ADT (7.3%), brachytherapy (5.1%) and high intensity focused ultrasound (0.7%) as primary treatment (median PSA value 1.6 ng/ml). Positivity rate was 80%. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence of bone and soft tissue lesions and number of bone, LN and soft tissue lesions, both in uni- and/or multivariable analysis. Multivariable analysis also showed prior ADT as predictor of bone and soft tissue lesions, GS as predictor of the number of bone lesions and ongoing ADT as predictor of the number of LN lesions. CONCLUSION: [(18)F]PSMA-1007-PET/CT showed a high positivity rate in patients with biochemically recurrent PCa. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence and number of bone and soft tissue lesions and the number of LN lesions. Our findings can guide clinicians in optimal patient selection for [(18)F]PSMA-1007-PET/CT and support further research leading to the development of a prediction nomogram. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-021-00783-w. |
format | Online Article Text |
id | pubmed-8087750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80877502021-05-05 Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer Ahmadi Bidakhvidi, Niloefar Laenen, Annouschka Jentjens, Sander Deroose, Christophe M. Van Laere, Koen De Wever, Liesbeth Mai, Cindy Berghen, Charlien De Meerleer, Gert Haustermans, Karin Joniau, Steven Everaerts, Wouter Goffin, Karolien EJNMMI Res Original Research BACKGROUND: Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [(18)F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and identify parameters that predict scan positivity as well as the type and number of detected lesions. This monocentric retrospective study included 137 PCa patients with biochemical recurrence who underwent one or more [(18)F]PSMA-1007-PET/CT scans between August 2018 and June 2019. PET-positive malignant lesions were classified as local recurrence, lymph node (LN), bone or soft tissue lesions. The association between biochemical/paraclinical parameters, as PSA value, PSA doubling time, PSA velocity, Gleason score (GS) and androgen deprivation therapy (ADT), and scan positivity as well as type and number of detected lesions was evaluated using logistic regression analysis (binary outcomes) and Poisson models (count-type outcomes). RESULTS: We included 175 [(18)F]PSMA-1007-PET/CT scans after radical prostatectomy (78%), external beam radiation therapy (8.8%), ADT (7.3%), brachytherapy (5.1%) and high intensity focused ultrasound (0.7%) as primary treatment (median PSA value 1.6 ng/ml). Positivity rate was 80%. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence of bone and soft tissue lesions and number of bone, LN and soft tissue lesions, both in uni- and/or multivariable analysis. Multivariable analysis also showed prior ADT as predictor of bone and soft tissue lesions, GS as predictor of the number of bone lesions and ongoing ADT as predictor of the number of LN lesions. CONCLUSION: [(18)F]PSMA-1007-PET/CT showed a high positivity rate in patients with biochemically recurrent PCa. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence and number of bone and soft tissue lesions and the number of LN lesions. Our findings can guide clinicians in optimal patient selection for [(18)F]PSMA-1007-PET/CT and support further research leading to the development of a prediction nomogram. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-021-00783-w. Springer Berlin Heidelberg 2021-04-30 /pmc/articles/PMC8087750/ /pubmed/33929626 http://dx.doi.org/10.1186/s13550-021-00783-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Ahmadi Bidakhvidi, Niloefar Laenen, Annouschka Jentjens, Sander Deroose, Christophe M. Van Laere, Koen De Wever, Liesbeth Mai, Cindy Berghen, Charlien De Meerleer, Gert Haustermans, Karin Joniau, Steven Everaerts, Wouter Goffin, Karolien Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title | Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title_full | Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title_fullStr | Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title_full_unstemmed | Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title_short | Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
title_sort | parameters predicting [(18)f]psma-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087750/ https://www.ncbi.nlm.nih.gov/pubmed/33929626 http://dx.doi.org/10.1186/s13550-021-00783-w |
work_keys_str_mv | AT ahmadibidakhvidiniloefar parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT laenenannouschka parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT jentjenssander parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT deroosechristophem parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT vanlaerekoen parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT deweverliesbeth parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT maicindy parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT berghencharlien parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT demeerleergert parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT haustermanskarin parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT joniausteven parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT everaertswouter parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer AT goffinkarolien parameterspredicting18fpsma1007scanpositivityandtypeandnumberofdetectedlesionsinpatientswithbiochemicalrecurrenceofprostatecancer |